Brooklyn Fundamentals

BTX
 Stock
  

USD 0.57  0.01  1.79%   

Brooklyn Immunotherapeutics fundamentals help investors to digest information that contributes to Brooklyn Immunotherapeuti's financial success or failures. It also enables traders to predict the movement of Brooklyn Stock. The fundamental analysis module provides a way to measure Brooklyn Immunotherapeuti's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brooklyn Immunotherapeuti stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.8 M) in 2022.

Brooklyn Z Score Analysis

Brooklyn Immunotherapeuti's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 (projected)
Receivables4.6 K4.72 K
Inventories900923.68
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Brooklyn Immunotherapeuti Z Score

    
  11.0  
Most of Brooklyn Immunotherapeuti's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brooklyn Immunotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

In accordance with the company's disclosures, Brooklyn Immunotherapeutics has a Z Score of 11.0. This is 62.96% higher than that of the Healthcare sector and 229.34% higher than that of the Biotechnology industry. The z score for all United States stocks is 26.15% lower than that of the firm.

Brooklyn Immunotherapeuti Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Brooklyn Immunotherapeuti's current stock value. Our valuation model uses many indicators to compare Brooklyn Immunotherapeuti value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brooklyn Immunotherapeuti competition to find correlations between indicators driving Brooklyn Immunotherapeuti's intrinsic value. More Info.
Brooklyn Immunotherapeutics is number one stock in gross profit category among related companies. It is number one stock in z score category among related companies . The ratio of Gross Profit to Z Score for Brooklyn Immunotherapeutics is about  426,364 . Brooklyn Immunotherapeuti Gross Profit is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Gross Profit of 11.09 Million in 2021. Comparative valuation analysis is a catch-all model that can be used if you cannot value Brooklyn Immunotherapeuti by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Brooklyn Immunotherapeuti's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brooklyn Immunotherapeuti's earnings, one of the primary drivers of an investment's value.

Brooklyn Immunotherapeuti Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brooklyn Immunotherapeuti from analyzing Brooklyn Immunotherapeuti's financial statements. These drivers represent accounts that assess Brooklyn Immunotherapeuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brooklyn Immunotherapeuti's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(210.27 K)(582.15 K)(212.89 K)(374.41 K)(430.57 K)(464.56 K)
Revenue Per Employee36.4 K63.14 K63.91 K33.11 K38.08 K52.38 K
Average Assets17.55 M15.62 M15.29 M8.94 M39.08 M42.17 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA1.8 M2.83 M1.4 M(7.19 M)(122.02 M)(125.23 M)
Earnings Before Interest Taxes and Depreciation Amortization USD1.8 M2.83 M1.4 M(7.19 M)(122.02 M)(125.23 M)
Earnings before Tax(1.01 M)(323 K)(2.02 M)(7.29 M)(122.48 M)(125.7 M)
Average Equity5.86 M6.39 M6.2 M3.48 M17.33 M18.69 M
Enterprise Value11.7 M6.81 M10.23 M8.31 M195.87 M211.33 M
Free Cash Flow(903 K)(214 K)1.65 M(8.14 M)(23.64 M)(24.26 M)
Invested Capital5.39 M9.38 M8.24 M9.01 M11.54 M10.79 M
Invested Capital Average5.34 M8.47 M11.74 M5.55 M10.2 M9.61 M
Market Capitalization10.61 M5.6 M6.38 M6.64 M217.02 M234.16 M
Tangible Asset Value14.11 M12.18 M11.51 M10.86 M29.48 M23.71 M
Working Capital(1.11 M)2.76 M(25 K)(1.39 M)15.09 M16.28 M

Brooklyn Fundamentals

About Brooklyn Immunotherapeuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue531.3 K545.3 K
Cost of Revenue8.6 M9.2 M
Revenues17.8 M19.2 M
Revenue to Assets 0.0195  0.02 
Revenue Per Employee38.1 K52.4 K
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Correlations Now

   

Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Altman Z Score analysis. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
32.6 M
Return On Assets
-0.65
Return On Equity
-17.6
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.